Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ONCY
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | Jared Kelly Chief Executive Officer, Director | ONCY Oncolytics Biotech Inc. | Buy | 5,050 | $0.96 | $4,848 Buy | Form 4 ↗ |
| Mar 11, 2026 | James T. Parsons Director | ONCY Oncolytics Biotech Inc. | Buy | 10,000 | $1.03 | $10.3K Buy | Form 4 ↗ |
| Feb 12, 2026 | Bernd R. Seizinger Director | ONCY Oncolytics Biotech Inc. | Buy | 40,000 | $0.85 | $34.0K Buy | Form 4 ↗ |
| Feb 12, 2026 | Wayne Pisano Director | ONCY Oncolytics Biotech Inc. | Buy | 30,000 | $0.84 | $25.2K Buy | Form 4 ↗ |
| Feb 12, 2026 | Kirk Look Chief Financial Officer | ONCY Oncolytics Biotech Inc. | Buy | 12,000 | $0.84 | $10.1K Buy | Form 4 ↗ |
| Feb 12, 2026 | Jared Kelly Chief Executive Officer, Director | ONCY Oncolytics Biotech Inc. | Buy | 29,500 | $0.84 | $24.8K Buy | Form 4 ↗ |
| Feb 12, 2026 | Thomas Charles Heineman Chief Medical Officer | ONCY Oncolytics Biotech Inc. | Buy | 12,132 | $0.83 | $10.1K Buy | Form 4 ↗ |
| Feb 12, 2026 | Allison Hagerman VP, Product Development | ONCY Oncolytics Biotech Inc. | Buy | 10,000 | $0.83 | $8,300 Buy | Form 4 ↗ |
| Feb 12, 2026 | Deborah Margaret Brown Director | ONCY Oncolytics Biotech Inc. | Buy | 25,000 | $0.85 | $21.3K Buy | Form 4 ↗ |
| Feb 12, 2026 | Patricia S. Andrews Director | ONCY Oncolytics Biotech Inc. | Buy | 35,400 | $0.86 | $30.4K Buy | Form 4 ↗ |
| Feb 11, 2026 | Bernd R. Seizinger Director | ONCY Oncolytics Biotech Inc. | Buy | 60,000 | $0.83 | $49.8K Buy | Form 4 ↗ |
| Feb 11, 2026 | Jared Kelly Chief Executive Officer, Director | ONCY Oncolytics Biotech Inc. | Buy | 5,600 | $0.84 | $4,704 Buy | Form 4 ↗ |
| Feb 11, 2026 | Andrew Aromando Chief Business Officer | ONCY Oncolytics Biotech Inc. | Buy | 29,600 | $0.86 | $25.5K Buy | Form 4 ↗ |
| Jan 16, 2026 | Bernd R. Seizinger Director | ONCY Oncolytics Biotech Inc. | Buy | 100,000 | $1.04 | $104.0K Buy | Form 4 ↗ |
14 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances